BMO Capital Maintains Outperform on Exelixis, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has maintained an 'Outperform' rating on Exelixis and raised its price target from $29 to $36, indicating a positive outlook for the company's stock.
October 30, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has maintained an 'Outperform' rating on Exelixis and increased the price target from $29 to $36, suggesting a positive short-term outlook for the stock.
The 'Outperform' rating and increased price target from a reputable analyst firm like BMO Capital suggest confidence in Exelixis's future performance, likely leading to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100